ESSA Pharma Inc (TSX-V: EPI)(NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported yesterday its financial results for the year ended 30 September 2018.
The company reported a net loss of USD11.6m for the year ended 30 September 2018, compared to a net loss of USD4.5m in the year-ago period.
The firm posted research and development expenditures for the year ended 30 September 2018 at USD4.9m net of grants compared to USD5.7m net of grants for the year ended 30 September 2017.
Cash on hand at 30 September 2018, was USD14.8m, with working capital of USD12.3m, reflecting the aggregate gross proceeds of the completed January 2018 financing, which totalled USD26m.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval